These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome. Zandee WT; Brabander T; Blažević A; Minczeles NS; Feelders RA; de Herder WW; Hofland J J Clin Endocrinol Metab; 2021 Aug; 106(9):e3665-e3672. PubMed ID: 33942075 [TBL] [Abstract][Full Text] [Related]
3. Radiopharmaceuticals used for diagnosis and therapy of NETs. Papachristou M Hell J Nucl Med; 2023; 26 Suppl():19-20. PubMed ID: 37658556 [TBL] [Abstract][Full Text] [Related]
4. Investigation of receptor radionuclide therapy with Nicolini S; Severi S; Ianniello A; Sansovini M; Ambrosetti A; Bongiovanni A; Scarpi E; Di Mauro F; Rossi A; Matteucci F; Paganelli G Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):923-930. PubMed ID: 29387927 [TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor radionuclide therapy in neuroendocrine tumors. Haider M; Das S; Al-Toubah T; Pelle E; El-Haddad G; Strosberg J Endocr Relat Cancer; 2021 Mar; 28(3):R81-R93. PubMed ID: 33608483 [TBL] [Abstract][Full Text] [Related]
6. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics. Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215 [TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914 [TBL] [Abstract][Full Text] [Related]
8. Clinical utility of Parghane RV; Naik C; Talole S; Desmukh A; Chaukar D; Banerjee S; Basu S Head Neck; 2020 Mar; 42(3):401-416. PubMed ID: 31755622 [TBL] [Abstract][Full Text] [Related]
9. Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC. Severi S; Sansovini M; Ianniello A; Bodei L; Nicolini S; Ibrahim T; Di Iorio V; D'Errico V; Caroli P; Monti M; Paganelli G Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1955-63. PubMed ID: 26112388 [TBL] [Abstract][Full Text] [Related]
11. Feasibility and therapeutic potential of the 68Ga/177Lu-DOTATATE theranostic pair in patients with metastatic medullary thyroid carcinoma. Dadgar H; Jafari E; Ahmadzadehfar H; Rekabpour SJ; Ravanbod MR; Kalantarhormozi M; Nabipour I; Assadi M Ann Endocrinol (Paris); 2023 Feb; 84(1):45-51. PubMed ID: 36126757 [TBL] [Abstract][Full Text] [Related]
12. Radionuclide Therapy for Neuroendocrine Tumors. Cives M; Strosberg J Curr Oncol Rep; 2017 Feb; 19(2):9. PubMed ID: 28220446 [TBL] [Abstract][Full Text] [Related]
13. Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors. Zandee WT; Brabander T; Blažević A; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; de Herder WW J Clin Endocrinol Metab; 2019 Apr; 104(4):1336-1344. PubMed ID: 30566620 [TBL] [Abstract][Full Text] [Related]
14. Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy. Minczeles NS; Hofland J; de Herder WW; Brabander T Curr Oncol Rep; 2021 Mar; 23(4):46. PubMed ID: 33721105 [TBL] [Abstract][Full Text] [Related]
15. [Theranostics for Well and Moderately Differentiated GEP-NEN]. Hartrampf P; Werner R; Buck A Zentralbl Chir; 2022 Jun; 147(3):249-255. PubMed ID: 35705086 [TBL] [Abstract][Full Text] [Related]
16. Peptide receptor radionuclide therapy (PRRT) for GEP-NETs. Bergsma H; van Vliet EI; Teunissen JJ; Kam BL; de Herder WW; Peeters RP; Krenning EP; Kwekkeboom DJ Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):867-81. PubMed ID: 23582925 [TBL] [Abstract][Full Text] [Related]
17. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807 [TBL] [Abstract][Full Text] [Related]
18. The effect of long-acting somatostatin analogues on the uptake of [ Veerman CHAM; Siebinga H; de Vries-Huizing DMV; Tesselaar MET; Hendrikx JJMA; Stokkel MPM; Aalbersberg EA Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1434-1441. PubMed ID: 36598536 [TBL] [Abstract][Full Text] [Related]
19. Tumor imaging and therapy using radiolabeled somatostatin analogues. de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476 [TBL] [Abstract][Full Text] [Related]